HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
Conditions: Efficacy and Safety Interventions: Drug: HR070803; Drug: Oxaliplatin; Drug: Tegafur; Drug: Folinic acid; Drug: 5-Fluorouracil Sponsors: The First Affiliated Hospital with Nanjing Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Eloxatin | Hospitals | Pancreas | Pancreatic Cancer | Research | Vitamin B9